Research Archives

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer

January 31, 2020

[Cancer Management and Research] FDA approval of ramucirumab has improved overall survival for patients with advanced gastric carcinoma; however, most patients do not achieve a cure, heightening awareness of health-related quality of life. This report focused on HRQoL and the impact of ramucirumab on HRQoL, as well as summarized studies evaluating the benefits of systemic therapies on HRQoL in patients with advanced gastric cancer.

Publishers Alliance

Radiotherapy for Patients With Completely Resected Pathologic IIIA(N2) Non-Small-Cell Lung Cancer: A Retrospective Analysis

January 24, 2020

[Cancer Management and Research] A retrospective review sought to determine the effect of postoperative radiotherapy on patients with stage IIIA(N2) non-small cell lung cancer with EGFR mutation.

Publishers Alliance

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

January 17, 2020

[Breast Cancer: Targets and Therapy] In this report, the researchers review the treatment of triple-negative breast cancer and specifically shed light on advances in immunotherapy and newly approved drugs for this challenging-to-manage disease.

Publishers Alliance

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

January 10, 2020

[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.

Blood and Lymphatic Cancer: Targets and Therapy

Publishers Alliance

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

January 3, 2020

[Blood and Lymphatic Cancer: Targets and Therapy] First approved in 2011, the CD30 directed antibody-drug conjugate brentuximab vedotin is used in previously untreated and R/R classical Hodgkin lymphoma (cHL). In this review, researchers discuss the expanded indications for BV in cHL to include maintenance therapy after ASCT and in combination with chemotherapy and immunotherapy.

Publishers Alliance

Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report

December 27, 2019

[OncoTargets and Therapy] Researchers outline the case of a 93-year-old female with advanced ATC who received initial treatment with apatinib.

Publishers Alliance

Time to Response in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib in the Phase II NP28673 and NP28761 Studies

December 20, 2019

[Lung Cancer: Targets and Therapy] Data from two phase 2 studies, NP28673 and NP28761, suggest that patients with previously treated ALK-positive NSCLC experienced rapid time to systemic response and time to CNS response with alectinib.

Publishers Alliance

Comparison of Accelerated Partial Breast Radiation Therapy and External Beam Radiation Therapy by Treatment Planning Indices

December 13, 2019

[Breast Cancer: Targets and Therapy] This study compared the technique, process, and outcomes of external beam radiation therapy with those of 3-dimensional conformal radiation therapy, finding that benefits of the APBI technique included fewer side effects and reduced treatment periods.

Publishers Alliance

Socioeconomic and Survival Differences Among Minorities With Hepatocellular Carcinoma in Florida

December 6, 2019

[Journal of Hepatocellular Carcinoma] In this study, investigators sought to determine how socioeconomic differences influenced outcomes for patients in Florida with HCC. They found that despite having lower socioeconomic status, Hispanic patients with HCC fared better than both black and white patients with HCC.

Multiple Myeloma, Publishers Alliance

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma

November 29, 2019

[OncoTargets and Therapy] In this review, researchers describe the pathophysiology of myeloma bone disease and discuss the significance of preventing skeletal-related events in patients with MM.

Diagnosis & Disease Information

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer

Radiotherapy for Patients With Completely Resected Pathologic IIIA(N2) Non-Small-Cell Lung Cancer: A Retrospective Analysis

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Initial Therapy of Advanced Anaplastic Thyroid Cancer via Targeting VEGFR-2: A Case Report

Time to Response in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib in the Phase II NP28673 and NP28761 Studies

Comparison of Accelerated Partial Breast Radiation Therapy and External Beam Radiation Therapy by Treatment Planning Indices

Socioeconomic and Survival Differences Among Minorities With Hepatocellular Carcinoma in Florida

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma

Systematic Nutrition Management for Locally Advanced Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy